4.6 Article

Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment

Journal

FRONTIERS IN NEUROLOGY
Volume 14, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2023.1230889

Keywords

spinal muscular atrophy; preterm; newborn screening; gene therapy; Zolgensma

Ask authors/readers for more resources

Spinal muscular atrophy is a genetic disorder that causes progressive muscle weakness and atrophy. Early therapeutic interventions are important for improving survival and outcomes. This study discussed a case of a preterm infant with spinal muscular atrophy who received early treatment with novel therapies.
Spinal muscular atrophy (SMA) is a neuromuscular genetic disorder caused by the loss of lower motor neurons leading to progressive muscle weakness and atrophy. With the rise of novel therapies and early diagnosis on newborn screening (NBS), the natural history of SMA has been evolving. Earlier therapeutic interventions can modify disease outcomes and improve survival. The role of treatment in infants born preterm is an important question given the importance of early intervention. In this study, we discuss the case of an infant born at 32 weeks who was diagnosed with SMA on NBS and was treated with Spinraza (R) (Nusinersen) and Zolgensma (R) (Onasemnogene abeparvovec-xioi) within the first 2 months of life. With the scarce evidence that currently exists, clinicians should be aware of the efficacy and safety impact of early therapy particularly in the preterm infant.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available